Navigation Links
MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
Date:9/18/2008

line in Biochemical and Biophysical Research Communications, scientists demonstrated that overexpressing miR-451 in-vitro caused inhibition of GBM cell growth. In addition, when combining Imatinib (Gleevec(R)), a targeted therapy manufactured by Novartis and approved treatment of CML and gastrointestinal stromal tumors, with miR-451, a synergistic effect has been shown in inhibiting GBM cell proliferation.

Imatinib (Gleevec(R)) is the first approved drug to directly inhibit a protein known to cause a cancer. Several studies have been, and are currently being conducted, to examine the drug's effectiveness in treating GBM.

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
2. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
3. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
4. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
5. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
6. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
9. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
10. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
11. The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  In part four of ... hospital pharmacy as a strategic asset, Mary Baxter, ... for Cardinal Health,s Innovation Delivery Solutions business, discusses how ... both hospitals and patients. "Every hospital pharmacist ... of their job in a value-based healthcare world," Baxter ...
(Date:8/29/2014)... DUBLIN , August 29, 2014 ... management and collaboration software has announced a major new ... services, founded by renowned pathology expert, Dr. Marius ... advance of the 26th European Congress of Pathology which ... in the ExCeL Arena, London ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: North America Aesthetic Lasers and ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North America ... 2020 Summary GlobalData,s new report, "North ... to 2020", provides key market data on the ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... May 6 Vanda Pharmaceuticals Inc. (Nasdaq: ... Drug Administration (FDA) has granted marketing approval of Fanapt(TM) ... schizophrenia. The approval was supported by two placebo-controlled Phase ... control in patients with schizophrenia, as well as safety ...
... provide important insight for physicians in treating heart attack ... BSX ) today welcomed the publication of ... issue of the New England Journal of Medicine. ... Foundation with research grant support from Boston Scientific and ...
Cached Medicine Technology:FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 2FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 3FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 4FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 5FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 6FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 7Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 2Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 3Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 4Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 5
(Date:8/30/2014)... Calif. (PRWEB) August 30, 2014 Insomnia causes ... helps listeners understand how they unknowingly developed insomnia and the ... restful nights during. Tune in to the show at ... The show airs live on August 30, and will be ... information on programming, go to DrCarolFrancisTalkRadio.com. , "Insomnia ...
(Date:8/30/2014)... Randy Dotinga HealthDay ... About one in five patients operated on for broken bones ... surgery, a new study finds. Less-educated patients and ... more likely to be "doctor shoppers," said study lead author ... Ky. Overall, he said, the study suggests that doctors aren,t ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Hastings and ... injury attorneys located throughout Arizona is pleased to report ... is one specific example among many cases where Hastings ... are able to retain a greater portion of their ... case that providing a positive solution for Arizona car ...
(Date:8/30/2014)... Administration of colchicine, a plant-based medication commonly used ... showed mixed results in reducing potential complications from ... the risk of gastrointestinal adverse effects, according to ... study is being released early online to coincide ... Cardiology Congress. , Common complications after cardiac surgery ...
(Date:8/30/2014)... 2014 "My niece developed a nighttime ... any moment, her fever might get worse," said an ... well aware of how she was doing, I developed ... to continuously monitor a child's temperature. The unit instantly ... ensures that prompt medical care can be given, which ...
Breaking Medicine News(10 mins):Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Medication shows mixed results in reducing complications from cardiac surgery 2
... Ind., April 14 Conseco, Inc. (NYSE:,CNO) ... promoted to vice president,enterprise risk management, reporting ... actuary. Mr. Bischof is responsible for overseeing ... conjunction,with Conseco,s Enterprise Risk Management Committee., ...
... April 14 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ), ... and audio web cast on Wednesday, April 30, 2008,at ... release of its,financial results for the first quarter ended ... 6:30 a.m. ET on Wednesday,April 30, 2008., To ...
... male hormone in the morning made more money , , MONDAY, ... finds that financial traders who wake up with high levels ... that day, probably because they feel more daring. , ... stress hormone cortisol tend to be more cautious. , "We ...
... The Pharmaceutical Care,Management Association (PCMA) issued the ... New York Times on skyrocketing biotech prices:, ... and will,spend $100 billion within a few years. ... because they don,t face generic competition once their,patents ...
... Cogdell Spencer,Inc. (NYSE: CSA ) announced today that ... on Monday, May 5, 2008. Cogdell Spencer,Inc. invites you ... May 6, 2008 at 10:00 a.m. (Eastern Time). The ... or (412) 858-4600,(international). In addition, the conference call can ...
... that hypertension should still be treated , , MONDAY, April ... are less likely to have headaches than those with ... one headache expert cautions that the new research does ... or stop taking their blood pressure medications. , The ...
Cached Medicine News:Health News:Testosterone Levels Among Financial Traders Affect Performance 2Health News:Testosterone Levels Among Financial Traders Affect Performance 3Health News:Cogdell Spencer Inc. Announces First Quarter Earnings Release and Conference Call Notice 2Health News:High Blood Pressure May Be Buffer Against Headaches 2Health News:High Blood Pressure May Be Buffer Against Headaches 3
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
... bags are part of the Freedom ... of leg bags, kits, and accessories ... of our customers. These leg bags ... constructed of 100% latex-free soft, textured ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: